Argenica Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Argenica Therapeutics heeft een totaal eigen vermogen van A$14.0M en een totale schuld van A$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk A$16.4M en A$2.4M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	n/a
Contant	AU$15.91m
Aandelen	AU$13.95m
Totaal verplichtingen	AU$2.43m
Totaal activa	AU$16.38m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$16.4M ) AGN } overtreffen de korte termijn passiva ( A$2.4M ).

Langlopende schulden: AGN heeft geen langlopende schulden.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: AGN is schuldenvrij.

Schuld verminderen: AGN heeft de afgelopen 5 jaar geen schulden gehad.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: AGN heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: AGN heeft voldoende kasruimte voor 2.6 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 35.6 % per jaar.

Argenica Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Ms. Liddy Mccall Intends Not Stand for Re-Election as Non-Executive Director of Argenica Therapeutics Limited

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

New minor risk - Share price stability

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

New major risk - Share price stability

Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing

Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee (SRC) to Progress to the Third Escalated Dose Cohort

Less than half of directors are independent

Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort

Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants

Argenica Therapeutics Limited Announces First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Argenica Therapeutics Limited Announces Further Positive Preclinical Results for ARG-007 in Hypoxic-Ischaemic Encephalopathy

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Announces Phase 1 Clinical Trial Summary

Argenica Therapeutics Limited Receives Ethics Approval to Commence Phase 1 Trial

Argenica Therapeutics Limited Submits Application to Seek Approval to Commence Phase 1 Healthy Participant Study of ARG-007

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Argenica Therapeutics Limited Announces Completion of the Final Pharmacokinetic (PK) Study of ARG-007 Required for the Phase 1 Clinical Trial

Less than half of directors are independent

Argenica Therapeutics Limited Announces Results of In-Life Rodent and Non-Human Primate Toxicology Studies Which Have Established the Maximum Tolerated Dose (MTD) of ARG-007

Less than half of directors are independent

Argenica Therapeutics Limited Announces Management Changes

Argenica Therapeutics Limited Announces Positive Preclincal Data on Efficacy of ARG-007

Argenica Therapeutics Limited Announces Successful Completion of Final GLP Genotoxicity Studies

Argenica Therapeutics Announces Completion of Preliminary Pre-Clinical Tox Studies

Argenica Therapeutics Limited Provides Additional Information of Study Shows ARG-007 Does Not Degrade

Argenica Therapeutics Limited Provides Positive Preliminary for ARG-007

Argenica Therapeutics Limited Completes Pilot Pre-Clinical Pharmacokinetics Study

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven